• Product NameAnacetrapib (MK-0859)
• Brief DescriptionInhibitors
• Purification99.61%
• Biological ActivityAnacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.
• Target NameCETP inhibitor
• CAS No. 875446-37-0
• Calculated MW 637.51
• Formulation C30H25F10NO3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Metabolism system
  SMILES:C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
  Pathways:Metabolism
  Receptor:Mutant CETP (C13S); rhCETP
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 127 mg/mL (199.21 mM); DMSO: 127 mg/mL (199.21 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Niesor EJ, et al. J Lipid Res. 2010, 51(12), 3443-3454.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting